Cerivastatin Gender Effect: Sub-analyses of Results from a Multinational, Randomised, Double-blind Study

SummaryWe previously reported the results of a multicentre, randomised, double-blind, parallelgroup study comparing the efficacy and safety of cerivastatin 0.4 mg/day and cerivastatin0.2 mg/day in patients with primary hypercholesterolaemia. Exploratory analysis in this study suggested a gender difference in the 0.4 mg group: mean low-density lipoprotein cholesterol (LDL-C) decreased by 44.4 ± 8.9% in women, compared with a mean decrease of 37.0 ± 0.9% in men (p 40%, compared with 38.0% (n = 76) of men taking the same dose. In the cerivastatin 0.2 mg PP population, 34% (n = 17) of women had an LDL-C decrease of > 40%, compared with 19% (n = 18) of men. Mean LDL-C/HDL-C ratio decreased by 43% from baseline to the end of the study in the cerivastatin 0.4 mg PP group: –41.3% in males vs. –48.3% in females. ...